Provision of a novel combined therapy with ECyd, which therapy exhibits remarkable antitumor effect and gives less adverse effects. The invention provides an antitumor agent containing, in combination, 1-(3-C-ethynyl-²-D-ribopentofuranosyl)cytosine or a salt thereof and carboplatin.
